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Anna Bonfitto 
TESTING BONE CELL MODELS RESPONSIVE TO A SOLUBLE FORM OF KLOTHO 
 
Fibroblast growth factor-23 (FGF23) is a hormone produced in bone that acts upon the 
kidney to control blood phosphate and 1,25-(OH)2 vitamin D concentrations.  Chronic 
kidney disease-mineral bone disorder (CKD-MBD) is a major public health problem, 
affecting 1 in 8 individuals.  These patients can have markedly elevated FGF23 at end 
stage disease which is associated with metabolic bone anomalies, left ventricular 
hypertrophy, as well as increased mortality (>6-fold).  The FGF23 co-receptor αKlotho 
(αKL) is a membrane-bound protein (mKL) that forms heteromeric complexes with FGF 
receptors (FGFRs) to initiate intracellular signaling.  It also circulates as a cleavage 
product of mKL (‘cleaved’, or cKL).  Previously, a patient with increased plasma cKL from 
a balanced translocation between chromosomes 9 and 13 in the KLOTHO gene 
presented with metabolic bone disease and a complex endocrine profile, despite 
hypophosphatemia.  The lack of a reliable cell model in which to study potential FGF23-
cKL interactions is a major hurdle for the field of phosphate metabolism.  The goal of the 
present studies was to test and characterize bone cell lines that may respond to FGF23 
and/or cKL, permitting study of novel aspects of phosphate handling and control of 
FGF23 expression.  It was confirmed that stable delivery of cKL via AAV2/8 to wild type 
(WT) and KL-KO mice resulted in highly elevated bone FGF23 mRNA.  MC3T3 (mouse) 
and ROS (rat) osteoblastic cell lines were tested for p-ERK1/2 responses to control FGFs, 
as well as FGF23 and cKL, alone or in combination.  Importantly, both cell lines 
v 
demonstrated responsiveness to FGF23+cKL only, and not the individual factors.  To test 
responsiveness at the cell level, EGR1 mRNA was tested as an index of FGFR activity and 
showed modest increases with the same treatments, supporting that other factors may 
be required for full transcriptional effects.  The present studies show that MC3T3 have 
FGF-dependent signaling capabilities, and that the combination of FGF23+cKL is 
required for efficient MAPK signaling.  These results demonstrated that cKL provision is 
permissive for efficient FGF23 signaling in bone, and revealed important implications for 
the regulation of FGF23 and cKL in Mendelian, and common, genetic disorders of 
phosphate handling and biomineralization. 
 
Kenneth E. White, Ph.D., chair  
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Introduction 
 
Phosphate 
 
Phosphate regulation 
Phosphorous is vital both structurally and functionally in mammals.  Inorganic 
phosphorus (Pi), the most common form utilized in biological processes such as 
development, bone formation, and cellular pathways, is present as an ion (PO4) [1].  In 
addition to being an integral part of the mammalian skeleton, phosphorus is also a 
crucial component of the backbone of nucleic acids.  A typical adult has a total 
phosphate serum level of 11-12 mg/dL, with 3-4 mg/dL being inorganic phosphate. 
Eighty-five percent of phosphorus is present in the form of hydroxyapatite in the 
skeleton and teeth [2, 3].   
 
Phosphorus homeostasis is maintained by a balance of absorption through the 
gastrointestinal tract and excretion by the kidneys [1], as well as retention and release 
of phosphorus in bones [4] (Figure 1).  The main source of phosphorus is dietary, and 
averages 20 mg/kg daily [5]; the majority of ingested phosphorus is absorbed through 
the intestine.  Further absorption is induced by the active form of vitamin D, 1,25-
(OH)2D.  The amount of 1,25-(OH)2D is determined in part by the enzymatic conversion 
from 25-hydroxy vitamin D by 1-α-hydroxylase (1α(OH)ase), which is produced by the 
kidney [6].   
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Phosphorus is excreted and reabsorbed in the kidneys according to levels of various 
factors, including vitamin D, parathyroid hormone (PTH) and fibroblast growth factor-23 
(FGF23).  Feedback loops ensure that phosphate levels are regulated in healthy 
individuals.  PTH increases the amount of vitamin D by upregulating 1-α hydroxylase, 
which causes more absorption of phosphate in the intestine [6].  The increase in 1,25-
(OH)2D then decreases the amount of PTH.  Higher vitamin D levels also upregulate 
FGF23 production to complete the feedback loop (Figure 1). 
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Figure 1 Phosphate handling 
Dietary phosphorus is absorbed by the intestines with the help of 1,25-(OH)
2
D, and is 
stored in the skeleton.  Phosphorus is also filtered by the kidneys; some is excreted in 
the urine and the amount needed to maintain appropriate blood phosphate levels is 
reabsorbed. 
4 
Metabolic disorders of phosphate dysregulation 
Autosomal dominant hypophosphatemic rickets (ADHR) is a disorder caused by a gain of 
function mutation of the gene FGF23 [7]. Mutations stabilize a cleavage site at amino 
acids 176-179 and the resulting increase in full-length FGF23 contributes to renal 
phosphate wasting.  Other symptoms of ADHR include rickets, osteomalacia, and 
inappropriately normal serum levels of 1,25-(OH)2D along with hypophosphatemia [1].  
In addition, it has been shown that a deficiency of iron upregulates expression of FGF23 
and contributes to the ADHR phenotype [8, 9]. 
 
Autosomal recessive hypophosphatemic rickets (ARHR) manifests similar phenotypes as 
ADHR, including deformities of the lower extremities, phosphate wasting, and normal 
1,25-(OH)2D serum levels along with hypophosphatemia [1].  Two genes have been 
associated with ARHR; mutations in both DMP1 and ENPP1 cause the disorder by loss of 
function [10-12].  A DMP1 null mouse model also showed severe skeletal muscle deficits 
[13].  Despite the underlying mutation, ARHR is characterized by high levels of FGF23 as 
in ADHR, but the mechanism is not as well understood [1]. 
 
X-linked hypophosphatemic rickets (XLH) shares features of ADHR and ARHR such as 
rickets, lower limb deformities, osteomalacia, hypophosphatemia, and inappropriately 
normal 1,25-(OH)2D levels in the serum [1].  FGF23 is also elevated in some patients with 
XLH, but the primary cause of phosphate wasting is excessive urinary excretion.  The 
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mutated gene for XLH is PHEX, located at Xp22.1; over 350 mutations have been found 
to cause disease [1, 14].  Although the specific mechanism for the loss of function of 
PHEX has not been elucidated, the loss does increase FGF23 levels and a PHEX transgene 
has been used to partially reverse mineralization defects in bones of a mouse model of 
XLH [15].  Also, the same phenomenon of iron upregulating FGF23 in ADHR has been 
observed in XLH [16]. 
 
Fibroblast Growth Factor-23 
FGF23 structure 
Fibroblast growth factor 23 (FGF23) is a hormone that was found to be the phosphaturic 
factor active in ADHR [7].  The structure of FGF23 is that of a glycoprotein; there are 251 
amino acids, and the C-terminal end binds to its co-receptor Klotho [17].  FGF23 is the 
product of three exons located at 12p13.3 [7].  High levels of serum phosphate and 
1,25-(OH)2D upregulate FGF23, which is primarily made by osteocytes and osteoblasts 
[17].  It has been determined that in the murine FGF23 promoter, the region from -200 
and -400 base pairs contains the element that responds to 1,25-(OH)2D [18]. 
 
FGF23 pathway and regulation 
Investigations have found that FGF23 is also a key factor in the phosphate wasting of 
several other hypophosphatemic disorders, including tumor-induced osteomalacia (TIO), 
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XLH, and ARHR [19].  FGF23 decreases levels of phosphate through inhibition of Npt2a 
and Npt2c, two renal phosphate cotransporters.  In addition to phosphate levels and 
1,25-(OH)2D, there is also evidence that FGF23 is upregulated by low iron levels [20].  
FGF23 is also part of a negative feedback loop that decreases the amount of 1,25-
(OH)2D. 
 
FGF23 tissues and organs 
Although FGF23 is produced in bone by osteocytes, the two main target organs are the 
kidney and parathyroid gland.  FGF23, along with the parathyroid hormone, act to 
downregulate the Npt2a and Npt2c transporters in the kidneys [17].  The kidney is also 
the primary site of action for FGF23 when bound to its co-receptor Klotho; FGF23 has 
also been recently shown to contribute to mineralization of bone in a pathway 
independent of Klotho and vitamin D levels [21]. 
 
Klotho 
Klotho structure 
αKlotho is found as both a membranous and a soluble protein.  The membranous form 
consists of 5 exons, whereas soluble Klotho contains 3 exons in mice and 5 exons in 
humans [22].  The human Klotho is at 13.33 in the genome; murine Klotho is on 
chromosome 5.  The membrane-bound form of Klotho (mKL) associates with FGF 
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receptors for FGF23-mediated intracellular signaling; the ‘cleaved’ portion of Klotho 
(‘cKL’) has been found to be a soluble co-receptor for FGF23. 
 
Klotho pathway and regulation 
Klotho decreases the amount of 1,25-(OH)2D by inhibiting 1-α-hydroxylase [23].  The 
gene was first identified from an advanced aging phenotype in deficient animals; the 
over-abundance of 1,25-(OH)2D and resulting hyperphosphatemia was thought to be the 
culprit of this phenotype by damaging organs [20].  Klotho also binds to FGF23, which 
increases the amount of phosphate excreted in the urine. 
 
Klotho tissues and organs 
The soluble form of Klotho is expressed in the pituitary gland, brain, testis, pancreas, 
thyroid, and kidneys [22]. Levels decrease early in the onset of chronic kidney disease, 
making it a potential biomarker for kidney function [24].  In addition, high levels of cKL 
in chronic hemodialysis patients has recently been associated with mortality risk [25].  
Klotho is highly expressed in the kidney, where the interaction with FGF23 occurs to 
regulate phosphate homeostasis by inhibiting Npt2a and Npt2c in the renal proximal 
tubules; the net effect is a decrease in blood phosphate concentrations (Figure 2).  
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Figure 2 FGF23 and cKL pathways 
Osteocytes produce FGF23, which is upregulated by increased serum phosphate, 
iron-induced anemia, and higher levels of vitamin D in the serum.  FGF23 contributes 
to the mineralization of bone; in concert with Klotho in the kidneys, FGF23 increases 
excretion of phosphate in the urine.  Klotho and FGF23 activity decrease the amount 
of active vitamin D by inhibiting the action of 1-α-hydroxylase. 
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cKL and FGF23 interactions 
An interesting patient presented with hypophosphatemic rickets and elevated FGF23 
levels [26].  The patient also had elevated serum PTH.  When nutrition was ruled out as 
an underlying cause of rickets, sequencing was performed.  Genes for FGF23, PHEX, and 
DMP1 showed no mutations; if the cause of hypophosphatemia and 
hyperparathyroidism was due to a previously described disorder of phosphate handling, 
a mutation in one of these genes would be expected.  Further testing was done by 
cytogenetics, and a balanced translocation was detected between chromosomes 9 and 
13.  The breakpoint, t(9,13)(q21.12;q13.1), occurred in the Klotho gene.  This patient 
represented a novel case where a Klotho gene rearrangement led to Klotho over-
expression and high serum levels of the cKL form as the cause of hypophosphatemia.   
 
In response to this case study, recent research utilizing a mouse model sought to further 
characterize the relationship between FGF23 and Klotho [27].  cKL was overexpressed in 
mice via adeno-associated virus (AAV) delivery to study the effect on FGF23.  Animals 
had significant increases in levels of bone FGF23 mRNA along with symptoms 
characteristic of FGF23-dependent hypophosphatemic disorders.   
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Chronic kidney disease-mineral bone disorder 
Mechanism 
Diabetes and high blood pressure are significant risk factors for developing chronic 
kidney disease (CKD), which is characterized by a gradual loss of kidney function.  As the 
kidneys lose their ability to excrete phosphate, FGF23 levels increase in an attempt to 
compensate.  FGF23 can be utilized as a marker for the progression of CKD by following 
plasma concentrations of both c-terminal and intact FGF23 protein [28].  FGF23 binds to 
Klotho in the kidneys, where the complex increases phosphate excretion; an 
overabundance contributes to hypophosphatemia in a healthy individual.  
Hyperphosphatemia from the organ’s reduced ability to excrete phosphate, along with 
left ventricular hypertrophy from elevated FGF23 levels, are major concerns in CKD 
patients.  Dialysis can help a patient’s overall health by filtering blood through an 
artificial kidney, but the specific problem of hyperphosphatemia is not alleviated by this 
therapy [29]. 
 
Incidence and impact 
CKD is a very common disease, affecting 1 in 8 people [30].  While rates of increase in 
the disease have tapered the last decade [31], CKD remains prevalent enough to 
increase health care costs and morbidity rates.  Hyperphosphatemia due to reduced 
kidney function is not the only complication from chronic kidney disease.  Associated 
deficiencies in bone and mineral metabolism have led to classification of CKD-mineral 
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and bone disorder (CKD-MBD) for most patients.  In addition to reduced kidney 
function, vascular calcifications and bone abnormalities may occur in CKD-MBD patients 
due to abnormal serum levels of 1,25-(OH)2D or phosphorus [32].  There are several 
other serious health consequences that can arise from CKD-MBD, including acute kidney 
injury, cardiovascular disease, and mortality [31].  
 
Hypothesis 
 
The interaction between FGF23 and Klotho plays an important role in CKD-MBD and 
other disorders of phosphate regulation.  A clinical case study involving a patient with 
hypophosphatemic rickets utilized cytogenetics when sequences of FGF23, PHEX, and 
DMP1 were consistent with wild-type sequences.  A balanced translocation that led to 
high serum Klotho was detected: t(9,13)(q21.12;q13.1) [26].  In addition to 
hypophosphatemia, serum levels of FGF23 were elevated in the patient.  This case 
highlights the complex interactions between FGF23 and cKL.  Therefore, a reliable bone 
cell model for these genes and their products would be beneficial for the study of 
phosphate handling disorders.  This project was intended to test the hypothesis that 
there is a suitable cell line for the study of FGF23 and Klotho interactions. 
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Materials and Methods 
 
WT and KL-KO mice 
Animal studies were performed according to the Institutional Animal Care and Use 
Committee (IACUC) for Indiana University, and comply with the NIH guidelines for the 
use of animals.  Adeno-associated virus expressing cKL (AAV-cKL, AAV-LacZ or vehicle 
phosphate-buffered saline, PBS) was delivered to 4 week old WT or αKL-null mice by 
retro-orbital injection at 1x1011 genomic copies/mouse.  All mice were euthanized by 
CO2 inhalation followed by cervical dislocation. 
 
WT and KL-KO AAV 
The cDNA encoding residues 35-983 of the extracellular domain of mouse cKL with a 
CD33 N-terminal signal sequence, or β-galactosidase gene cassette (LacZ) as a control, 
was packaged into a recombinant hybrid adeno-associated viral vector 2/8 (AAV; 
RegenX Biosciences). 
 
ROS (rat osteoblast) and MC3T3 (mouse osteoblast) cell lines 
Cells were cultured in MEMα (Sygma) supplemented with 10% fetal bovine serum, 1% 
sodium pyruvate (Gibco by Life Technologies), 1% L-glutamine 100x solution (Hyclone), 
and 1% Penicillin-Streptomycin solution (Hyclone).  Cells were incubated with 5% CO2 at 
37˚ C and medium was replaced after 2-3 days. 
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Immunoblotting 
Cells were seeded at 1.0x105 cells per well in 12-well plates.  Each well was treated for 
10 minutes with 30 nM cKL, 115 nM FGF23, or a combination of 30nM cKL and 115nM 
FGF23 and washed once with PBS as previously described [33].  Control wells were 
treated for ten minutes with 1 µl of either FGF2 or FGF8 (100 ng/mL) and washed with 
PBS.  Each well was immediately harvested with 250 µl of 1x cell lysis buffer (Cell 
Signalling) with 0.1% 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF, 
Santa Cruz).  Lysates were collected in 1.7 ml microcentrifuge tubes and stored at -20˚ C. 
 
Lysates thawed on ice were boiled for five minutes and centrifuged at maximum speed 
for one minute.  Protein concentrations were obtained by Coomassie Plus (Bradford) 
Assay kit (ThermoScientific).  Fresh Laemmli Sample Buffer (BioRad) with 5% β-
mercaptoethanol (Fisher Scientific) was added to samples in an equal volume.  Samples 
were then electrophoresed on an Any KD Mini-Protean TGX gel (BioRad); 30 µg of lysate 
was loaded in each well.  TransBlot Turbo transfer system (BioRad) was used to transfer 
gel material to a 0.2um PVDF membrane for 3 minutes. 
Membranes were blocked in a solution of 5% dry milk powder (Scientific Inc.) in 1xTBS 
(Tris-buffered saline, BioRad) for one hour at room temperature.  Primary antibody was 
added according to Table 1 and incubated overnight at 4˚ C.  Membranes were given 
four, ten-minute washes with 1xTBS and 0.05% Tween 20 (USB Corporation).  Secondary 
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antibody was added to membranes for one hour at room temperature according to 
Table 1; membranes were then washed three times for ten minutes per wash with 
1xTBS and 0.05% Tween 20.  Enhanced chemoluminescence (ECL, GE Healthcare) was 
used to detect horseradish peroxidase (HRP) activity and membranes were imaged with 
the Amersham Imager 600 by GE. 
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Table 1  Antibodies for western blot 
 
 Antibody Vendor Dilution 
Primary (rabbit) 
Phospho-ERK Cell Signaling 1:1000 
Total ERK Promega 1:1000 
Phospho-AKT Cell Signaling 1:2000 
Secondary 
Goat Anti-Rabbit 
IgG-HRP Conjugated 
Bio-rad 1:2000 
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RNA isolation and qPCR 
Cells in 12-well plates, 1.0x105 cells per well, were treated overnight with equal 
amounts of the indicated factors.  Wells were washed once with PBS and harvested with 
300 µl of RLT lysis buffer from the RNeasy Mini kit (Qiagen, Inc).  Lysates were stored at 
-20˚ C if not used immediately.  Either fresh lysates or those thawed on ice were then 
processed for RNA extraction following the RNeasy Mini kit protocol.  Femur/bone RNA 
from mice was harvested using Trizol reagent (Life Technologies) as previously 
described[33] 
 
Extracted RNA samples were diluted with RNAse-free water for a concentration of 10 
ng/µl.  Each well of a MicroAmp Optical 96-well reaction plate (Applied Biosystems) 
contained 12.5 µl TaqMan RT-PCR mix (2x), 0.625 µl TaqMan RT Enzyme Mix (40x), 
0.375 µl RNase free water, 0.5 µl 10 µM forward primer, 0.5 µl 10 µM reverse primer, 
and 0.5 µl 5 µM probe.  Primers are described in Table 2.  The quantitative PCR program 
on the StepOnePlus Real-Time PCR System (Thermo Fisher) was 30 min 48˚ C, 10 min 95˚ 
C, then 40 cycles of 15 sec 95˚ C and 1 min 60˚ C.  Samples were analyzed in duplicate 
using the comparative CT (∆∆CT) experiment workflow.  The fold change of gene 
expression was tested by the 2-∆∆CT method.  Comparisons of control RNA expression 
and test sample RNA expression were calculated by Student’s t-test with a threshold of 
p<0.05. 
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Table 2 Real-time PCR primers 
 
 
Gene Forward primer Reverse primer Probe Vendor 
Mouse 
FGF23 
5’CCTTCTCCCAGTT
CCTGGC 3’ 
5’GGGCGAACA
GTGTAGAAATG
C 3’ 
5’ FAM-
CGCAGGAACGAGGTCC
CGCTG-TAMRA 3’ 
IDT 
ABI 
5’ 
AGCCGAGCGAACA
ACCCTAT 3’ 
5’ 
CGCCTTCTCATT
ATTCAGAG 3’ 
5’ FAM-
AGCACCTGACCACAGA
GTCCTTTTCTGACA-
TAMRA 3’ 
IDT 
Mouse 
C-fos 
PURCHASED 
FROM ABI 
PROPIETARY 
SEQUENCE 
CAT #: 
Mm00487425_m1 
ABI 
Rat 
EGR1 
5’ 
AGCGCTTTCAATCC
TCAAGC 3’ 
5’ 
CAGAAAAGGAC
TCTGTGGTCAG
G 3’ 
5’ FAM-
AGCCGAGCGAACAACC
CTACGAG TAMRA3’ 
IDT 
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Results 
 
FGF23 and cKL measurements obtained from animal studies 
The in vivo relationship between FGF23 and cKL was first established in wild-type 
animals.  cKL was administered to experimental animals by AAV and control animals 
received phosphate buffered saline (PBS).  Fold changes in FGF23 mRNA increased 
significantly (p<0.05) in animals given cKL versus controls (Figure 3).  Control mice given 
PBS (n=4) averaged 1.4 copies of FGF23 and mice administered cKL (n=5) averaged 354.4 
FGF23 copies. 
 
The relationship between FGF23 and cKL was further tested in mice with Klotho knocked 
out.  Klotho knock-out mice (KL KO) were compared to wild type mice as well as to KL 
KO mice administered with cKL (Figure 4).  Bone mRNA was isolated and analyzed for 
FGF23 mRNA; FGF23 is primarily produced in bone, so induction of transcription would 
be evident from bone samples.  Knock out animals showed a significant increase in 
FGF23 mRNA in the bone compared to wild type animals.  When cKL was given to KL KO 
animals, there was additional increase in FGF23 mRNA levels versus PBS-treated KL KO 
controls.  Egr1 mRNA was also tested from the bone of wild type, KL KO, and KL KO 
given cKL mice (Figure 5).  Egr1 has been identified as a factor that responds to FGF23-
cKL activity [34, 35].  Although there was a trend, Egr1 mRNA levels in either KL KO mice 
or KL KO mice given cKL did not differ significantly (p<0.07) from wild type mice.  
19 
Potentially, the long-term nature (4 weeks) of this study may have resulted in 
compensatory control and normalization of Egr1. 
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Figure 3 FGF23 fold-changes by qPCR in wild type animals  
Wild type animals were treated with either PBS or cKL and FGF23 mRNA from bone 
samples was analyzed.  Animals treated with cKL showed significantly higher FGF23 
mRNA levels (354.4 copies) than control animals (1.4 copies), p<0.05 (*).  Error bars 
indicate SD. 
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Figure 4 FGF23 percent changes in KL KO mice  
Klotho knockout mice showed a significant increase in FGF23 mRNA compared to wild 
type mice, p<0.001 (*).  FGF23 mRNA was further increased in comparison to wild 
type when knock out animals were administered cKL, but the increase was not 
significant by Student’s t-test (p<0.07).  Error bars indicate SD. 
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Figure 5 EGR1 mRNA changes in KL KO mice   
The amount of EGR1 mRNA from the bones of KL KO mice did not differ significantly 
(p<0.32) from EGR1 mRNA levels in wild type mice, although there was a slight 
increase.  KL KO mice given cKL also did not show a significant change in EGR1 mRNA 
compared to wild type mice.  Error bars indicate SD. 
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C-fos, another indicator of FGF23-cKL activity [34, 35], was compared in KL KO animals 
and KL KO animals administered cKL (Figure 6).  The levels of Egr1 mRNA from bone 
samples were similar between both groups, as were c-fos mRNA levels.  Although c-fos 
levels were slightly higher than Egr1 levels, there was not a significant increase (p<0.28). 
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Figure 6 EGR1 and C-fos mRNA from KL KO mice   
mRNA isolated from bones of KL KO animals given cKL was analyzed for Egr1 and C-fos 
mRNA levels.  Despite a slight increase, there was no significant difference when 
compared to KL KO control animals (n=5, p<0.28). 
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Assessing FGF23 and Klotho activity in cell model studies 
Two murine cell lines were examined to search for a suitable model to test FGF23-
Klotho interactions and bioactivity.  ROS (rat osteoblast) cells and MC3T3 (mouse 
osteoblast) cells were both cultured and exposed to cKL and FGF23, and the mRNA 
encoding the transcription factor Egr1 was used as a readout for FGF and cKL activity. 
FGF2 and FGF8 were added to cell cultures as positive controls for Egr1 activity.  RNA 
extracted from lysates of cells treated with PBS, FGF2, FGF8, FGF23, Klotho, and a 
combination of FGF23+Klotho were tested for Egr1 mRNA levels as an indicator of cell 
responsiveness.  In ROS cells, a significant increase in Egr1 mRNA was seen only in cells 
treated with the positive control FGF2; the experimental conditions of adding FGF23, 
Klotho, or FGF23+Klotho did not induce activity in the cells (Figure 7).  MC3T3 cells had 
higher Egr1 mRNA compared to PBS negative control conditions in cells treated with the 
positive control FGF8 and in cells treated with the combination of FGF23 and Klotho 
(Figure 8).  The increase in activity induced by FGF23+Klotho indicates that MC3T3 cells 
are responsive to a combination of FGF23 and Klotho activity.  MC3T3 cells treated with 
Klotho alone also exhibited an increase in Egr1 mRNA levels compared to MC3T3 cells 
treated with FGF23 alone.  
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Figure 7  Egr1 mRNA fold-changes in ROS cells  Cells in culture were treated with 
either PBS, FGF2, FGF8, Klotho, FGF23, or Klotho+FGF23.  Resulting lysates were 
tested for Egr1 mRNA by qPCR. ROS cells treated with FGF2 showed a significant 
increase in Egr1 mRNA, p<0.05 (*).  Only a modest increase in Egr1 mRNA was seen in 
cells treated with both cKL and FGF23.  Experiment was repeated once. 
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Figure 8  Egr1 mRNA fold-changes in MC3T3 cells  MC3T3 cells treated with cKL or 
FGF23 alone showed no effects, however a combination of cKL+FGF23 increased 
expression of Egr1 mRNA compared to PBS (untreated), p<0.05 (**). The positive 
control FGF8 increased Egr1 mRNA p<0.005 (*).  There is also a significant increase 
of Egr1 mRNA in FGF23-treated cells compared to those treated with cKL, p<0.0001 
(‡).  Error bars indicate SD.  PBS (n=5); FGF2 (n=3); FGF8 (n=4); Klotho (n=3); FGF23 
(n=4); KL+FGF23 (n=5). 
28 
ROS cells were also probed by western blot for phospho-Erk (p-Erk) and total Erk protein 
levels (Figure 9).  Lysates from cells treated with FGF2 or FGF8 showed strong signal 
compared to untreated cells for p-Erk along with lysates treated with a combination of 
FGF23 and Klotho.  Increased signal on the blot corresponds to increased expression of 
the protein that is being probed, so this result shows the combination of FGF23 and 
Klotho increase the amount of Erk that is phosphorylated in ROS cells.  The 
phosphorylated Erk indicates that the treatment induced the MAPK pathway.  The 
profile for total Erk was the opposite: stronger signals were seen for lysates of cells 
treated with PBS, FGF23 alone, and Klotho alone.  MC3T3 cells were also 
immunoblotted blotted for p-Erk and total Erk (Figure 10).  The same signal strengths 
were seen as in the ROS cells; FGF2, FGF8, and the combination of FGF23 and Klotho 
increased protein expression of p-Erk.  MC3T3 cells also produced more total Erk when 
treated with PBS, FGF23 alone, and Klotho alone. 
 
In summary, the results show that cKL and FGF23 delivered together have bioactivity in 
bone. The studies with WT and KL KO mice confirm that administering cKL induced 
FGF23 expression in vivo.  Furthermore, as shown in the MC3T3 and ROS cell lines, a 
combination of cKL and FGF23 were required to increase cell signaling of the pERK 
activity. Importantly, these studies show that both cell lines respond to cKL and FGF23 
administration, and thus provide new cell models for mechanistic testing as well as 
targeting bone cKL-FGF23 bioactivity.     
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Figure 9 Western blot of treated ROS cells   
Lysates from treated ROS cells were probed for phospho-ERK, total ERK, and 
phospho-AKT (loading control).  Positive controls FGF2 and FGF8 showed strong 
signal for phospho-ERK, as well as lysates from cells treated with Klotho and FGF23 
in combination.  Total ERK showed strong signal for PBS, Klotho alone, and FGF23 
alone treated lysates.  Repeated once; values quantitated by ImageJ. 
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  Figure 10 Western blot of treated MC3T3 cells  
Lysates from treated ROS cells were probed for phospho-ERK and total ERK.  
Positive controls FGF2 and FGF8 showed strong signal for phospho-ERK, as well as 
lysates from cells treated with Klotho and FGF23 in combination.  Total ERK showed 
strong signal for PBS, Klotho alone, and FGF23 alone treated lysates. Repeated 
once; values obtained by ImageJ analysis.  
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Discussion 
 
Rationale  
A major consideration for the management of CKD-MBD is lowering phosphate levels of 
patients.  A better understanding of the interactions between FGF23 and Klotho with 
respect to the impact on phosphate metabolism will help guide research for 
therapeutics.  Klotho, in particular, is not yet well understood.  Although it has been 
shown in animal models that the protein has atheroprotective effects, high levels of 
Klotho have been associated with higher mortality rates in CKD patients [24].  This risk 
of severe complications makes cKL problematic as a treatment for hyperphosphatemia 
in CKD and CKD-MBD patients, although treating patients with cKL is an appealing 
option for reducing serum phosphate levels.  A reliable cell model for Klotho studies 
would be useful in determining more detailed pathways involving FGF23 and Klotho, 
and also potential therapeutics targeting these or other proteins in the relevant 
pathways.  The aim of this thesis was to study potential cell models that could serve the 
purpose of FGF23 and Klotho testing. 
 
Klotho upregulates FGF23 in vivo 
The in vivo data assembled here reinforces the relationship between FGF23 and Klotho.  
qPCR data showed induction of FGF23 mRNA expression in wild type mice when treated 
with cKL via adenoviral delivery.  This result indicates that FGF23 mRNA is directly 
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upregulated by increased cKL levels.  An increase in FGF23 mRNA was also seen in 
Klotho knock out mice that were administered cKL.  This result also shows the positive 
effect of cKL on the amount of FGF23 mRNA.  In both of these mice models, cKL clearly 
upregulated FGF23.  This relationship agrees with results found in a previous study that 
utilized AAV-delivered cKL in a mouse model [27].  The levels of FGF23 were also 
increased according to the amount of cKL delivered. 
 
Klotho and FGF23 interact in vitro 
One function of Klotho is the regulation of FGFRs.  When Klotho forms heteromeric 
complexes with FGFRs in the kidney, FGF23 is able to bind very strongly to this receptor 
complex [20].  ROS (rat osteoblast) and MC3T3 (mouse osteoblast) cell lines were tested 
with FGF23 and cKL to find a model that potentially reflected the relationship between 
FGF23 and cKL that is seen in mouse models.  Cell models may be more useful for 
studies that require large screens.  Egr1 is known to be activated by the FGF23-cKL 
complex [34]; this mRNA was measured in cells treated overnight with a combination of 
FGF23 and cKL.  Cell were incubated for the optimal time to allow transcription of Egr1 
to occur.  The results were inconclusive for the ROS cells with regard to Egr1 as an early 
indicator of the action of FGF23 combined with Klotho.  MC3T3 cells, however, exhibited 
the expected FGF23-cKL activity response as evidenced by increased Egr1 mRNA levels.  
These results indicate that of the two cell lines tested, MC3T3 may be a better choice for 
the study of FGF23-cKL in vitro. 
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In addition to qPCR studies to measure mRNA levels, immunoblotting for protein 
expression levels was also performed on cKL- and FGF23-treated ROS and MC3T3 cells.  
Total Erk and phosphorylated Erk, a member of the MAPK pathway, were probed to 
detect FGF23-cKL activity [36].    Erk activity, probed for as phosphorylated Erk, was 
detected in both of the controls, FGF2 and FGF8, and also in cells treated with a 
combination of FGF23 and Klotho [33].  Although the ROS cells showed a response in 
phosphorylated Erk protein, there was not an increase in Egr1 mRNA when treated with 
a combination of FGF23 and Klotho.  On the other hand, protein and mRNA data from 
MC3T3 cells indicate they are promising as a means of further studying FGF23-cKL 
interactions; both mRNA and protein assays show that MC3T3 cells respond to FGF23-
cKL. 
 
Future research 
Future directions for research include testing agonist/antagonist models to aid in 
phosphate homeostasis for CKD patients.  Results from this study indicate that MC3T3 
cells are more appropriate for the study of FGF23-cKL interaction based on the protein 
and mRNA studies. Therapies that target either Klotho or FGFRs could be used to 
regulate the action of FGF23 in the kidneys by affecting the binding of the complex. 
These therapies could increase the affinity for FGF23, which could decrease phosphate 
reabsorption and promote the phosphaturic action of FGF23.  While FGFRs were not 
tested here, the MC3T3 cell line may be useful in terms of FGF23 and Klotho interactions 
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with FGFRs.  In addition, based on the findings presented in this thesis, the MC3T3 line 
could be used to test small molecules capable of interacting with FGF23, Klotho, FGFRs, 
or the FGF23-cKL complex. 
 
In addition to Klotho and associated FGFRs, FGF23 itself can be studied as a potential 
therapeutic target.  Indeed, the anti-FGF23 antibody therapeutic ‘KRN23’ is undergoing 
clinical trials [37]. Certainly, targeting FGF23 in late stage disease could potentially 
ameliorate the ‘off target’ cardiovascular manifestations of markedly elevated FGF23 
[38]. Additionally, promoter studies using the FGF23 promoter could provide the 
molecular mechanisms whereby Klotho regulates FGF23 transcription. Indeed, previous 
promoter studies have identified key elements for the 1,25D regulation of FGF23 [18, 
39].  If the exact portion of the promoter responsive to Klotho is ascertained, the direct 
effect of Klotho on FGF23 could potentially be controlled.  For example, experiments 
could include isolating the promoter and performing pull-down assays with Klotho.  
MC3T3 cells have been shown to be responsive to FGF23-cKL activity and would be an 
ideal model for testing various promoters in vitro after initial protein studies were 
complete. 
 
Conclusions 
The mice data presented herein agreed with previous studies [27] characterizing the 
relationship between FGF23 and Klotho.  Sustained delivery of cKL to mice has been 
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shown to increase FGF23 mRNA [27], and the same results were duplicated when mRNA 
from bone was probed for FGF23.  ROS cells and MC3T3 bone cells were compared for 
their FGF23-cKL activity.  Although both cell lines reflected FGF23-cKL protein activity as 
seen on western blots, only MC3T3 cells showed an increase in Egr1 mRNA by qPCR 
analysis as an early indicator of FGF23-cKL activity.  In conclusion, the MC3T3 cell line is 
a promising tool for the study of FGF23-cKL interactions, which could lead to future 
targeting of this pathway to control FGF23 production in both rare and complex 
diseases.    
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